Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Development of Bioscavengers for U.S. Army

by Global Biodefense Staff
September 1, 2014

The U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) is seeking services to develop rapidly absorbed and persistent bioscavengers.

Bioscavengers are proteins that react specifically and quickly with organophosphate (OP) chemical agents without causing undesirable side-effects.

Medical chemical mitigation by bioscavengers is a promising means of protection against nerve agent toxicity. Two of the important desirable bioscavenger characteristics include rapid absorption of bioscavengers from an IM dose into the blood stream and persistence of this bioscavenger in the blood.

Under the proposed contract, USAMRICD wants to make use of mouse red blood cell (RBC) epitopes to target bioscavengers to RBCs. Therapeutic proteins delivered in this manner could potentially improve the retention times as great as the native RBC of 120 days. With such treatment it would be possible to retain higher effective concentrations of the therapeutic proteins and reduce or eliminate multiple dosing.

The means of the work will be to create an immunized domain Nb library by immunizing a llama or camel with the target protein ECD and mouse RBCs. RNA is extracted from splenocytes (or lymphocytes) and by PCR methods amplified and the VHH regions cloned into filamentous bacteriophages to produce a protein display library. The library is initially screened to isolate binders. The select library is then screened to identify high-affinity single domain binders. The identified high-affinity Nb genes will then be sequenced.

Further details are available under Solicitation Number: W81XWH-14-T-0461. The response deadline is September 8, 2014.

Tags: Bioscavengers

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy